[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correspondence
April 2007

National Eczema Association and Topical Calcineurin Inhibitor Labeling

Arch Dermatol. 2007;143(4):543-551. doi:10.1001/archderm.143.4.546-a

The National Eczema Association for Science and Education (NEASE) is the representative and the advocate for 20 million people in the United States who have eczema problems, and I write on their behalf. Our major concern is the well-being of the patients we represent. The detailed comments by Stern1 on the decision-making process used by the external pediatric committee in advising the US Food and Drug Administration (FDA) regarding topical calcineurin inhibitors raise several issues that are useful to place into public discussion.

First Page Preview View Large
First page PDF preview
First page PDF preview
×